Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer

August 25th, 2014 Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Merck, known as MSD outside the United States and Canada, through its subsidiaries, to evaluate the combination of Advaxis’s Lm-LLO cancer immunotherapy, ADXS-PSA, with Merck’s investigational anti PD-1 antibody, pembrolizumab. The planned clinical trial will evaluate the safety and efficacy …

A new Immunotherapy Technology Developed at Yale University Helps Patients Own Immune Cells Fight Cancer

Immune Cell Cancer Fighting Activity Boosted By Nanomaterials

A new Immunotherapy Technology Developed at Yale University Helps Patients Own Immune Cells Fight Cancer Researchers at Yale University have developed a new technology which uses a sample of a cancer patients immune cells and grows them in the lab, using carbon nanotube-polymer composites. When these enhanced immune cells are injected back into the patients body, the immune cancer-fighting response …

Regen BioPharma Has Reported Progress in Development of dCellVax: A Therapeutic Cancer Vaccine

Regen BioPharma Advances Towards Breast Cancer Immunotherapy

Regen BioPharma Has Reported Progress in Development of dCellVax: A Therapeutic Cancer Vaccine On the 1st of August 2014, Regen BioPharma reported on progress on its therapeutic cancer vaccine dCellVax, which stimulates the immune system of patients to selectively kill tumors. Thomas Ichim, the Chief Scientific Office of Regen BioPharma, said in a statement that ‘we are please to announce …

Moffitt Cancer Center Begins Phase I Clinical Trial of New Immunotherapy

April 9, 2014 Moffitt Cancer Center has initiated a phase I clinical trial for a new immunotherapy drug, ID-G305, made by Immune Design. Immunotherapy is a treatment option that uses a person’s own immune system to fight cancer. It has several advantages over standard cancer therapies, including fewer side effects and an overall better tolerability. It tends to be most effective …

TapImmune Announces the Filing of New Intellectual Property for its Platform Expression System Polystart

New Technology Significantly Enhances the Presentation of Desired Peptides on the Surface of Cells for Targeting to the Immune System March 20, 2014 TapImmune Inc., a clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease has filed a new patent application for a novel technology platform designed to enhance …

Ludwig & Agenus to Advance Three Checkpoint Modulator Antibodies

March 5, 2014 Ludwig Cancer Research and Agenus Inc. today announced the selection of three monoclonal antibody checkpoint modulators (CPMs) that Agenus is advancing into preclinical development. These product candidates—two GITR agonists and a CTLA-4 antagonist—target cell-surface checkpoint proteins that control immune responses. They are part of Agenus’ recent acquisition of 4-Antibody AG and the result of several years of intensive collaborative efforts …

Genocea Biosciences Announces Collaboration to Characterize T Cell Responses to Cancer Antigens

March 3, 2014 Genocea Biosciences, Inc., a company pioneering novel T cell vaccines and immunotherapies, today announced a joint research collaboration with Dana-Farber Cancer Institute and Harvard Medical School to characterize anti-tumor T cell responses in melanoma patients. This collaboration extends the use of the company’s proprietary ATLAS™ platform for the rapid discovery of T cell antigens to cancer immunotherapy approaches. “ATLAS™ has proven …

Kidney Cancer Care Improves With Vaccine-Based Approach

February 18, 2014 The Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute has opened a novel Phase III, vaccine-based clinical trial aimed at providing kidney cancer patients long-term control of their disease. Survival outcomes for patients with renal cell carcinoma, the most common form of kidney cancer, have improved significantly over the past decade due to research advances in personalized or “targeted” therapies designed to target …